Search Results
Your search for ,New matches 16912 pages
Showing 9801 - 9850Tales From the OR: A Pediatric Surgeon’s Memoir
CARING FOR sick children brings with it a set of emotional and physical challeneges that differ from those with the adult patient population. In a new book, Healing Children: A Surgeon’s Stories From the Frontiers of Pediatric Medicine, Kurt Newman, MD, draws on more than 30 years of his...
A Doctor’s Call to Arms About the Overuse of Antibiotics
On September 3, 1928, Scottish biologist Alexander Fleming returned to London from a vacation and sorted through some petri dishes containing colonies of Staphylococcus. He noticed something unusual in one dish: It was dotted with colonies except for one area where a patch of mold grew....
A New Manual for the Expanding Field of Bone Marrow Transplantation
The first hematopoietic stem cell transplant was pioneered by E. Donnall Thomas, MD, and published in The New England Journal of Medicine in September 12, 1957. Although the six patients on his trial all died by 100 days post transplantation, Dr. Thomas remained undaunted, continuing his...
The Rising Incidence of Thyroid Cancer Reconsidered
Despite a significant rise in the incidence of thyroid cancer, the U.S. Preventive Services Task Force (USPSTF), a panel of independent experts in primary care and screening, has given thyroid cancer screening a D recommendation, which is a recommendation against screening. To shed light on this...
Expert Point of View: David Maloney, MD, and Kenneth C. Anderson, MD
SIMILAR CELLULAR immunotherapies are currently being developed and tested by other National Cancer Institute–designated cancer centers, including Fred Hutchinson Cancer Research Center. David Maloney, MD, Medical Director of Cellular Immunotherapy at Fred Hutchinson and Medical Director of the...
FDA Approves First CAR T-Cell Therapy for Pediatric, Young Adult Patients With ALL
ON AUGUST 30, 2017, the U.S. Food and Drug Administration (FDA) approved tisagenlecleucel (Kymriah) for pediatric and young adult patients up to 25 years with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory to initial treatment or in second or later relapse. Tisagenlecleucel ...
Pembrolizumab in Classical Hodgkin Lymphoma
On March 14, 2017, pembrolizumab (Keytruda) was granted accelerated approval for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma or those who have relapsed after three or more prior lines of therapy.1,2 Supporting Efficacy Data APPROVAL WAS BASED on...
Global Cancer Institute Launches New Patient Navigation Program to Accelerate Treatment for Patients in Brazil
GLOBAL CANCER INSTITUTE (GCI), focused on survival and quality of underserved patients with cancer worldwide, has announced it is launching a new Patient Navigation Program in Rio de Janeiro, Brazil. The program went live in early August 2017 and is intended to help promote adherence to Brazil’s...
FDA Announces New Comprehensive Plan for Tobacco and Nicotine Regulation
Recently, the U.S. Food and Drug Administration (FDA) announced a new strategy to address tobacco-related disease and death. The agency seeks to develop a plan to reduce the nicotine levels in combustible cigarettes to nonaddictive levels. However, as part of the strategy, the FDA also announced it ...
Get to Know Your ASCO President-Elect: Monica M. Bertagnolli, MD, FASCO
Monica M. Bertagnolli, MD, FASCO, a long-time member and volunteer, began her term as ASCO President-Elect in June 2017; she will serve as 2018–2019 ASCO President. An active ASCO member since 1995, Dr. Bertagnolli is Chief of the Division of Surgical Oncology at Dana-Farber/Brigham and Women’s...
Emerging Global Leaders in Biosimilar Development: Regulatory Guidance and Cost Impact
BIOLOGICS PLAY A KEY ROLE in cancer treatment and are the principal components of many therapeutic regimens.1 However, they require complex manufacturing processes, resulting in high cost and occasional shortages in supply, limiting the accessibility of cancer treatment for many patients, more so ...
Addressing the Societal Impact of Financial Toxicity
Most discussions about “financial toxicity” center on the cancer patient, but there is also a societal toxicity, which has far-reaching consequences. Coming up with answers to this growing problem has vexed health-care experts over the past decade. In an effort to gather opinions on this vital...
Positioning Lu-177 Dotatate Therapy and 68-Ga Dotatate Scans in Management of Neuroendocrine Tumors
The results of the phase III NETTER-1 trial, recently published in The New England Journal of Medicine,1 have been met with great interest by clinicians who treat neuroendocrine tumors. In patients with advanced midgut lesions, treatment with the radiopharmaceutical lutetium Lu-177 dotatate...
Initiating the Topic of Weight and Health With Patients With Obesity
Rates of obesity have been steadily rising over the past 3 decades in both adults and children. Today, more than one-third of American adults and about 17% of children and adolescents, ages 6 to 19, have obesity.1 Cancer rates have risen in tandem with obesity rates, making obesity the second...
Fred Hutch Launches Pathogen-Associated Malignancies Integrated Research Center
Fred Hutchinson Cancer Research Center (Fred Hutch) is launching a new integrated research center to prevent and find cures for cancers caused by infectious agents. It will be led by Denise Galloway, PhD, a Fred Hutch microbiologist whose research paved the way for the human papillomavirus (HPV)...
Testing Alpha-Emitting Radiolabeled Immunotherapy to Treat—and Potentially Cure—Multiple Myeloma
Despite a flurry of treatment advances in multiple myeloma over the past decade that have increased overall survival from just 2 to 3 years in the 1990s to between 5 and 7 years today—with some data suggesting an extended life expectancy of between 7 and 10 years1—the cancer remains stubbornly...
Prostate Cancer Foundation Announces 2017 Young Investigator Awards Recipients
The Prostate Cancer Foundation has announced its 2017 Young Investigator (YI) Awards, which support early-career scientists who are focused on accelerating the delivery of life-extending and life-saving therapies for patients living with prostate cancer. The YI Awards provide 3 years of funding—a...
Edith Peterson Mitchell, MD, Awarded ASTRO Honorary Membership
Edith Peterson Mitchell, MD, a leading researcher, medical oncologist, and proponent of combined-modality treatment, has been chosen as the 2017 American Society for Radiation Oncology (ASTRO) Honorary Member. Dr. Mitchell will receive this award—which is the highest honor ASTRO awards to...
Pediatric Cancer Research Collective Awarded Millions by NIH
A public-private research collective was awarded up to $14.8 million from the National Institutes of Health (NIH) to launch a data resource center for cancer researchers around the world to accelerate the discovery of novel treatments for childhood tumors. Contingent on available funds, 5 years of...
Peter W.T. Pisters, MD, MHCM, Named Sole Finalist in Search for President, MD Anderson
The University of Texas System Board of Regents has selected Peter W.T. Pisters, MD, MHCM, as sole finalist for the position of President at The University of Texas MD Anderson Cancer Center in Houston. The regents voted unanimously to select Dr. Pisters at a special board meeting on Friday,...
Journal of Clinical Oncology Literature Update
Staying up-to-date in the fast-paced world of oncology literature is a daunting task at best. To assist with that task, The ASCO Post has assembled an assortment of studies recently published in the Journal of Clinical Oncology. The topics range from therapy for stage IV non–small cell lung cancer...
Long-Term Follow-up in PIVOT Trial Shows No Significant Benefit of Surgery vs Observation for Overall or Prostate Cancer Mortality
After 19.5 years of follow-up in the PIVOT trial, radical prostatectomy was not associated with significantly improved all-cause or prostate cancer mortality vs observation among men with localized prostate cancer.1 The long-term follow-up was reported in The New England Journal of Medicine by...
Award for Early Career Scientists in New York: Applications Open October 2, 2017
The Pershing Square Sohn Cancer Research Alliance (PSSCRA) will open for applications for its 2018 Pershing Square Sohn Prize for Young Investigators on October 2, 2017. At least six New York City area–based scientists will each be awarded $200,000/year—for up to 3 years—to enable them to pursue...
Non–Small Cell Lung Cancer: Emerging Concepts for Checkpoint Inhibitors
With checkpoint inhibitors vitally important in the treatment of advanced non–small cell lung cancer (NSCLC), clinicians must become familiar with the nuances of their use. At the 2017 Debates and Didactics in Hematology and Oncology Conference in Sea Island, Georgia, Suresh S. Ramalingam, MD,...
Recent FDA Actions Include New Formulation, Expanded Indications for Oncology-Hematology Drug Products
The U.S. Food and Drug Administration (FDA) recently granted approval to olaparib tablets (Lynparza) as a maintenance therapy for ovarian cancer and to inotuzumab ozogamicin (Besponsa), for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)....
Multiple Myeloma: Researchers Are Digging Deeper Than Ever
Researchers are tackling multiple myeloma from many angles, and the result could be a flood of novel approaches soon within the oncologist’s reach, according to Kenneth C. Anderson, MD. At the 2017 Debates and Didactics in Hematology and Oncology Conference at Sea Island, Georgia, Dr. Anderson...
Targeted Treatments and Health-Related Quality of Life in Ovarian Cancer
Novel targeted treatment strategies and new trial endpoints in recurrent, platinum-sensitive ovarian cancer were highlighted in a gynecologic cancer session at the Best of ASCO New Orleans. At the meeting, Karen McLean, MD, PhD, of the University of Michigan Medical Center, Ann Arbor, presented...
For the Impoverished, Health Care Is a Luxury
Cancer is the second leading cause of death worldwide, and the global burden is on an inexorably upward trajectory. For the year 2012, there were 14.1 million new cancer cases and 8.2 million cancer-related deaths worldwide.1 It is predicted that by the year 2035, there will be 23.9 million new...
Long-Term Follow-up of PIVOT Argues for Immediate Treatment of Men With Unfavorable-Risk and Possibly High-Volume, Low-Risk Prostate Cancer
The updated results of the PIVOT1 study—reported in The New England Journal of Medicine by Wilt et al and reviewed in this issue of The ASCO Post—did not show a statistically significant difference between treatment and observation for the initial management approach to men with newly diagnosed...
Update on Hematopoietic Cell Transplant Includes New Data in HIV-Infected and Follicular Lymphoma Patients
New hematology research, presented at the Best of ASCO New Orleans meeting, may help to guide the use of stem cell transplant in hematologic malignancies. At the meeting, Guillermo Garcia-Manero, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, and Tycel Phillips, MD, of the...
FDA Approves Gemtuzumab Ozogamicin for Treatment of Acute Myeloid Leukemia
The U.S. Food and Drug Administration (FDA) today approved gemtuzumab ozogamicin (Mylotarg) for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) whose tumors express the CD33 antigen. The drug was also approved for the treatment of patients aged 2 years and older with...
Genetic Variant May Significantly Lower Risk of Breast Cancer in Women With History of Preeclampsia
Researchers have demonstrated that women with a history of preeclampsia have as much as a 90% decrease in breast cancer risk if they carry a specific common gene variant. Further studies are now underway to determine the mechanism of this protection in an effort to develop new breast cancer...
FDA Statement Regarding Safety Concerns Related to Investigational Use of Pembrolizumab in Multiple Myeloma
On August 31, U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research Director Janet Woodcock, MD, issued the following statement: “Clinical trials play a critically important role in bringing to market innovative new therapies for patients facing life-threatening...
ASCO Publishes Resources for Cancer Care Providers and Patients Affected by Hurricane Harvey
In the aftermath of the devastation caused by Hurricane Harvey throughout the state of Texas, which has resulted in more than 30,000 people being displaced from their homes, ASCO has published a list of resources and information for oncology providers and patients with cancer affected by the...
Artificial Intelligence May Help With Earlier Detection of Skin Cancer
New technology being developed by researchers at the University of Waterloo and the Sunnybrook Research Institute is using artificial intelligence (AI) to help detect melanoma at earlier stages. The technology employs machine-learning software to analyze images of skin lesions and provide...
Adipose Tissue and Cancer Risk
Although obesity and its associated metabolic dysregulation are established risk factors for many cancers, the biologic mechanisms underlying this relationship are not well understood. Now, the results from a systematic literature review by Himbert et al of human clinical studies exploring the...
FDA Approves First CAR T-Cell Therapy for Pediatric and Young Adult Patients With B-Cell Precursor ALL
Today, the U.S. Food and Drug Administration (FDA) issued what it has called a “historic action,” making the first gene therapy available in the United States. The FDA approved tisagenlecleucel (Kymriah) for certain pediatric and young adult patients with a form of acute lymphoblastic...
FDA Grants Breakthrough Therapy Designation to DS-8201 for HER2-Positive Metastatic Breast Cancer
On August 29, Daiichi Sankyo announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody-drug conjugate, for the treatment of patients with HER2-positive, locally advanced or metastatic breast cancer...
Tivozanib Approved in the European Union for the Treatment of Advanced Renal Cell Carcinoma
On August 28, AVEO Oncology announced that the European Commission (EC) has approved tivozanib (Fotivda) for the treatment of adult patients with advanced renal cell carcinoma in the European Union plus Norway and Iceland. Tivozanib is indicated for the first-line treatment of adult patients with...
Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors
In a single-center phase II study reported in JAMA Oncology, Feng et al found that individualized adaptive stereotactic body radiotherapy achieved high rates of local tumor control with low complication rates in patients with liver tumors and preexisting liver dysfunction. Study Details The study ...
Association of Systemic Inflammation and Sarcopenia With Survival in Early-Stage Colorectal Cancer
Results from the C SCANS (Colorectal Cancer: Sarcopenia, Cancer, and Near-Term Survival) study indicate that prediagnosis systemic inflammation and at-diagnosis sarcopenia are associated with an increased mortality risk in patients with nonmetastatic colorectal cancer. The findings were reported in ...
FDA Accepts sBLA, Grants Priority Review for Obinutuzumab in Previously Untreated Follicular Lymphoma
On August 28, the U.S. Food and Drug Administration (FDA) accepted the supplemental Biologics License Application (sBLA) and granted Priority Review for obinutuzumab (Gazyva) in combination with chemotherapy followed by obinutuzumab alone for patients with previously untreated follicular lymphoma....
Metastasis-Free Survival as Surrogate for Overall Survival in Localized Prostate Cancer
In a meta-analysis reported in the Journal of Clinical Oncology, Xie et al found that metastasis-free survival was a strong surrogate for overall survival in patients with localized prostate cancer, potentially providing a metric that could accelerate assessment of new adjuvant therapy approaches. ...
2018 Pershing Square Sohn Cancer Research Prize Opens for Applications on October 2, 2017
The Pershing Square Sohn Cancer Research Alliance (PSSCRA) will begin accepting applications for its 2018 Pershing Square Sohn Prize for Young Investigators on October 2, 2017. At least six New York City area–based scientists will each be awarded $200,000 per year—for up...
Concurrent Treatment With OX40 Agonist Antibody and PD-1 Blockade
Although the potential for immunotherapy to improve outcomes for patients with cancer, particularly through a combination of agents targeting immune inhibitory pathways, is becoming increasingly evident, how to optimally combine the many new immunotherapy agents being developed remains a major...
HPV Vaccination Rates Especially Low Among Childhood Cancer Survivors
The rate of human papillomavirus (HPV) vaccination in the United States is increasing, but remains lower than ideal. A new study suggests that survivors of childhood cancer receive the HPV vaccine at an even lower rate than their peers without cancer—24% vs 40%, respectively. Nearly...
Palliative Care May Substantially Decrease Health-Care Utilization in Patients With Advanced Cancer
A new population-based study shows that palliative care substantially decreased health-care utilization among Medicare beneficiaries with advanced cancer, resulting in less intensive care being delivered at the end of life. This included lower rates of hospitalization, fewer invasive procedures,...
Women More Likely Than Men to Experience Response After Induction Chemoradiotherapy and Esophagogastrectomy for Esophageal Cancer
Female patients with locally advanced esophageal cancer treated with chemotherapy and radiation therapy before surgery are more likely to have a favorable response to the treatment than male patients are, and women are less likely to experience cancer recurrence, according to a study published by...
Nodal Stage Migration and Prognosis in Anal Cancer
In a study reported in The Lancet Oncology, Sekhar et al found that the increasing proportion of lymph node–positive disease associated with enhanced detection techniques has led to nodal stage migration in anal cancer, which may reduce prognostic discrimination on the basis of lymph node...
Medical Costs and HPV Vaccination in Oropharyngeal Cancer
According to the Centers for Disease Control and Prevention, human papillomavirus (HPV)-related cancers, including oropharyngeal, vulvar, cervical, vaginal, penile, anal, and rectal cancers, have increased in recent years, with oropharyngeal cancer the most common HPV-related cancer—from 2008 ...
